Thomas Yunger, MD
Pulmonary Disease · Dayton, OHNPI 1962496844
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $318,035 of the $352,960 with a category attached, or 90.1%. GSK accounts for 95.4% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2019 at $98,949 and has fallen 72.3% since, to $27,378 in 2025. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,084 payments — averaging $325.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$337K
- Boehringer Ingelheim$5K
- AstraZeneca$3K
- Grifols USA, LLC$1K
- Regeneron Healthcare Solutions, Inc.$891
- Sanofi$873
- plus $6K from 32 others
Across 21 payments — averaging $2284.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$30K
- GSK$8K
- Sanofi US Services Inc.$6K
- Shire North American Group Inc$3K
- Boehringer Ingelheim$1K
What the payments were for
- Consulting fees$140%
- Speaking & faculty fees$318,03590%
- Travel & lodging$12,6724%
- Food & beverage$22,0276%
- Education$1940%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 441 | $336,602 |
| Boehringer Ingelheim | 90 | $4,878 |
| AstraZeneca(2 entities) | 142 | $2,818 |
| Grifols USA, LLC | 60 | $1,102 |
| Regeneron Healthcare Solutions, Inc. | 35 | $891 |
| Sanofi | 36 | $873 |
| Genentech USA, Inc. | 50 | $819 |
| Actelion Pharmaceuticals US, Inc. | 48 | $677 |
| Viiv Healthcare Company | 1 | $600 |
| Inspire Medical Systems, Inc. | 13 | $555 |
| Merck | 28 | $415 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $377 |
| United Therapeutics Corporation | 17 | $337 |
| Axsome Therapeutics, Inc. | 17 | $305 |
| Jazz Pharmaceuticals Inc. | 12 | $205 |
| Amgen | 10 | $189 |
| Pulmonx Corporation | 6 | $185 |
| Insmed, Inc. | 7 | $138 |
| Mylan Specialty L.p. | 8 | $131 |
| Baxter Healthcare | 4 | $121 |
| Teva Pharmaceuticals USA, Inc. | 7 | $117 |
| Bayer | 6 | $106 |
| Lilly USA, LLC | 1 | $90 |
| Gilead | 4 | $71 |
| Novartis | 4 | $64 |
| Kaleo, Inc. | 3 | $47 |
| Verona Pharma, Inc. | 2 | $43 |
| Viatris Specialty LLC | 2 | $31 |
| Shire North American Group Inc | 2 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Shionogi Inc | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| AbbVie | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$170,601
- AREXVY$72,626
- NUCALA$18,507
- ANORO$8,413
- Inspire$375
- FASENRA$349
- DUPIXENT$314
- BREZTRI$230
- AIRSUPRA$222
- ANORO ELLIPTA$109
How this compares
$352,960 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 68 | $748,303 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 598 | $645,244 |
| Tyvaso DpiTreprostinil | 11 | $269,984 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $203,496 |
| AdempasRiociguat | 11 | $155,213 |
| OpsumitMacitentan | 12 | $153,841 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 194 | $151,165 |
| Breo ElliptaFluticasone/Vilanterol | 186 | $115,273 |
| Spiriva RespimatTiotropium Bromide | 91 | $109,898 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $91,687 |
| TezspireTezepelumab-Ekko | 21 | $88,094 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 102 | $85,439 |
| NucalaMepolizumab | 14 | $59,966 |
| EliquisApixaban | 45 | $31,591 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $20,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $336,602 | $987,9781,017 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $4,878 | $963,884284 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Bevespi Aerosphere, Symbicort | $2,818 | $200,291126 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Bosentan | $677 | $170,10225 claims |
| BayerAdempas | $106 | $155,21311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Dayton
- Daniel PearsonDayton$61K
- Rajesh PatelDayton$54K
- Ravi DesaiDayton$34K
- Anuj GoyalDayton$28K
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.